ALX Oncology
ALXO
69 hedge funds and large institutions have $189M invested in ALX Oncology in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 12 closing their positions.
465% more capital invested
Capital invested by funds: $33.5M → $189M (+$156M)
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
54% more call options, than puts
Call options by funds: $156K | Put options by funds: $101K
21% more funds holding
Funds holding: 57 → 69 (+12)
17.76% more ownership
Funds ownership: 53.87% → 71.63% (+18%)
Top Buyers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$24.8M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$24.8M |
| 3 |
Blackstone Inc
New York
|
+$11.1M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$8.95M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$8.21M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$2.32M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$537K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$521K |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$508K |
| 5 |
Jane Street
New York
|
-$173K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$17.1K | -15,102 | Closed |
|
|
VF
77
Virtu Financial
New York
| – | -$15K | -13,702 | Closed |
|
78
Simplex Trading
Chicago,
Illinois
| – | -$6.77K | -3,553 | Closed |
|
|
TRCT
79
Tower Research Capital (TRC)
New York
| – | -$3.55K | -3,142 | Closed |
|
|
TM
80
Torren Management
San Diego,
California
| – | -$1.84K | -1,632 | Closed |
|
81
Group One Trading
Chicago,
Illinois
| – | -$987 | -518 | Closed |
|
ALXO Hedge Fund Activity: Q1 2026 in Review
69 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q1 2026, worth a combined $189M — up 465% from $33.5M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ALXO positions and 12 closed out — a net gain of 13 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $24.8M. The largest seller was Millennium Management, cutting an estimated $2.32M.
- 69 institutional investors held ALX Oncology (ALXO) as of Q1 2026, up from 57 in Q4 2025.
- Funds reported $189M of ALX Oncology stock for Q1 2026, up 465% quarter-over-quarter.
- 25 funds opened new ALX Oncology positions in Q1 2026 and 12 closed out, a net change of +13 holders.
- The largest ALX Oncology buyer in Q1 2026 was RA Capital Management, an estimated $24.8M added.
- The largest ALX Oncology seller in Q1 2026 was Millennium Management, an estimated $2.32M sold.
Based on aggregated 13F filings for Q1 2026.